Table 1 Clinical characteristics (201 patients)
Characteristic | Median (range) | No. | % | |
|---|---|---|---|---|
Gender | ||||
Male | 150 | 74.6 | ||
Female | 51 | 25.4 | ||
Age (years) | 60 (28–80) | |||
<60 | 99 | 49.3 | ||
≥60 | 102 | 50.7 | ||
Pathological type | ||||
Squamous carcinoma | 67 | 33.3 | ||
Adenocarcinoma | 108 | 53.7 | ||
others | 26 | 13.0 | ||
T stage | ||||
T1-2 | 74 | 36.8 | ||
T3-4 | 127 | 63.2 | ||
N stage | ||||
N0-1 | 35 | 17.4 | ||
N2-3 | 166 | 82.6 | ||
Prescribed dose | 63 (22–72) | |||
<63Gy | 108 | 53.7 | ||
≥63Gy | 93 | 46.3 | ||
No. of chemotherapy cycle | 4 (1–5) | |||
1 | 19 | 9.5 | ||
2 | 45 | 22.4 | ||
3 | 44 | 21.9 | ||
4 | 89 | 44.3 | ||
5 | 4 | 2.0 | ||
No. of metastatic sites | 1 (1–5) | |||
1 | 121 | 60.2 | ||
2 | 55 | 27.4 | ||
3 | 20 | 10.0 | ||
4 | 4 | 2.0 | ||
5 | 1 | 0.5 | ||
Response of primary tumor | ||||
Complete response | 12 | 6.0 | ||
Partial response | 113 | 56.2 | ||
Stable | 40 | 19.9 | ||
Progressive | 16 | 8.0 | ||
Unassessable | 20 | 10.0 | ||
Radiotherapy to metastasis | ||||
Patients with 1 metastatic site | Yes | 76 | 62.8 | |
No | 45 | 37.2 | ||
Patients with ≥2 metastatic sites | Yes | 22 | 27.5 | |
No | 58 | 72.5 | ||